Mohammed T. Abou-Saleh

216 PRINCIPLES AND PRACTICE OF GERIATRIC PSYCHIATRY21. Levy-Lahad E, Wijsman EM, Nemens E et al. A familial Alzheimer’sdisease locus on chromosome 1. Science 1995; 269: 970–3.22. Farrer LA. Genetics and the dementia patient. Neurologist 1997; 3:13–30.23. Pericak-Vance MA, Bebout JL, Gaskell PC et al. Linkage studies infamilial Alzheimer disease: evidence for chromosome 19 linkage. AmJ Hum Genet 1991; 48: 1034–50.24. Strittmatter WJ, Saunders AM, Schmechel D et al. Apolipoprotein E:high-avidity binding to B-amyloid and increased frequency of type 4allele in late-onset familial Alzheimer disease. Proc Natl Acad SciUSA 1993; 90: 1977–81.25. Schmechel DE, Saunders AM, Strittmatter WJ et al. Increasedamyloid B-peptide deposition in cerebral cortex as a consequence ofapolipoprotein E genotype in late-onset Alzheimer disease. Proc NatlAcad Sci USA 1993; 90: 9649–53.26. Mayeux R, Stern Y, Ottman R et al. The apolipoprotein E4 allele inpatients with Alzheimer’s disease. Ann Neurol 1993; 34: 752–4.27. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. ApolipoproteinE in sporadic Alzheimer’s disease: allelic variation and receptorinteractions. Neuron 1993; 11: 575–80.28. Saunders AM, Strittmatter WJ, Schmechel D et al. Association ofapolipoprotein E allele E4 with late-onset familial and sporadicAlzheimer’s disease. Neurology 1993; 43: 1467–72.29. Brousseau T, Legrain S, Berr C et al. Confirmation of the E4 allele ofthe apolipoprotein E gene as a risk factor for late-onset Alzheimer’sdisease. Neurology 1994; 44: 342–4.30. Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose ofapolipoprotein E type 4 allele and the risk of Alzheimer’s disease inlate onset families. Science 1993; 261: 921–3.31. Roses AD. Apolipoprotein E alleles as risk factors in Alzheimerdisease. Ann Rev Med 1996; 47: 387–400.32. Farrer LA, Cupples LA, Haines JL et al. Effects of age, sex, andethnicity on the association between apolipoprotein E genotype andAlzheimer disease. J Am Med Assoc 1997; 278: 1349–55.33. Nalbantoglu J, Gilfix BM, Bertrand P et al. Predictive value ofapolipoprotein E genotyping in Alzheimer’s disease: results of anautopsy series and an analysis of several combined studies. AnnNeurol 1994; 36: 889–95.34. Roses AD, Devlin B, Conneally PM. Measuring the geneticcontribution of APOE in late-onset Alzheimer disease. Am J HumGenet 1995; 57: A202.35. Breitner JCS, Wyse BW, Anthony JC et al. APOE-epsilon4 countpredicts age when prevalence of AD increases, then declines: theCache County Study. Neurology 1999; 53: 321–31.36. Pericak-Vance MA, Bass MP, Yamaoka LH et al. Complete genomicscreen in late-onset familial Alzheimer disease. Evidence for a newlocus on chromosone 12. J Am Med Assoc 1997; 278: 1237–41.37. Scott WK, Grubber JM, Conneally PM et al. Fine mapping of thechromosome 12 late-onset Alzheimer disease locus: potential geneticand phenotypic heterogeneity. Am J Hum Genet 2000; 66: 922–32.38. Rogaeva E, Premkumar S, Song Y et al. Evidence for an Alzheimerdisease susceptibility locus on chromosome 12 and for further locusheterogeneity. J Am Med Assoc 1998; 280: 614–18.39. Wu W, Holmans P, Wavrant-DeVrieze F et al. Genetic studies onchromosome 12 in late-onset Alzheimer disease. J Am Med Assoc1998; 280: 619–22.40. Rebeck GW, Harr SD, Strickland DK, Hyman BT. Multiple, diversesenile plaque-associated proteins are ligands of an apolipoprotein Ereceptor, a 2 -macroglobulin receptor/low-density-lipoprotein receptorrelatedprotein. Ann Neurol 1995; 37: 211–17.41. Kounnas MZ, Moir RD, Rebeck GW et al. LDL receptor-relatedprotein, a multifunctional ApoE receptor, binds secreted b-amyloidprecursor protein and mediates its degradation. Cell 1995; 82: 331–40.42. Kang DE, Saitoh T, Chen X et al. Genetic association of the lowdensitylipoprotein receptor-related protein gene (LRP), an apolipoproteinE receptor, with late-onset Alzheimer’s disease. Neurology1997; 49: 56–61.43. Lendon CL, Talbot CJ, Craddock NJ et al. Genetic associationstudies between dementia of the Alzheimer’s type and three receptorsfor apolipoprotein E in a Caucasian population. Neurosci Lett 1997;222: 187–90.44. Wavrant-De Vrie` ze F, Pe´rez-Tur J, Lambert JC et al. Associationbetween the low-density lipoprotein receptor-related protein (LRP)gene and Alzheimer’s disease. Neurosci Lett 1997; 227: 68–70.45. Hollenbach E, Ackermann S, Hyman BT, Rebeck GW. Confirmationof an association between a polymorphism in exon 3 of the lowdensitylipoprotein receptor-related protein gene and Alzheimer’sdisease. Neurology 1998; 50: 1905–7.46. Lambert JC, Vrieze FW-D, Amouyel P, Chartier-Harlin M-C.Association at LRP gene locus with sporadic late-onset Alzheimer’sdisease. Lancet 1998; 351: 1787–8.47. Clatworthy AE, Gomez-Isla T, Rebeck W et al. Lack of associationof a polymorphism in the low-density lipoprotein receptor-relatedprotein gene with Alzheimer disease. Arch Neurol 1997; 54: 1289–92.48. Fallin D, Kundtz A, Town T et al. No association between the lowdensity lipoprotein receptor-related protein (LRP) gene and late-onsetAlzheimer’s disease in a community-based sample. Neurosci Lett1997; 233: 145–7.49. Blacker D, Wilcox MA, Laird NM et al. Alpha-2 macroglobulin isgenetically associated with Alzheimer disease. Nature Genet 1998; 19:357–60.50. Liao A, Nitsch RM, Greenberg SM et al. Genetic association of ana2-macroglobulin (Val1000lle) polymorphism and Alzheimer’s disease.Hum Mol Genet 1998; 7: 1953–6.51. Myllykangas L, Polvikoski T, Sulkava R et al. Genetic association ofa 2 -macroglobulin with Alzheimer’s disease in a Finnish elderlypopulation. Ann Neurol 1999; 46: 382–90.52. Chen L, Baum L, Ng HK et al. Apolipoprotein E promoter andalpha2-macroglobulin polymorphisms are not genetically associatedwith Chinese late-onset Alzheimer’s disease. Neurosci Lett 1999; 269:173–7.53. Crawford F, Freeman M, Town T et al. No genetic associationbetween polymorphisms in the Tau gene and Alzheimer’s disease inclinic- or population-based samples. Neurosci Lett 1999; 266: 193–6.54. Dow DJ, Lindsey N, Cairns NJ et al. a-2 macroglobulinpolymorphism and Alzheimer disease risk in the UK. NatureGenet 1999; 22: 16–17.55. Rogaeva EA, Premkumar S, Grubber J et al. An a-2-macroglobulininsertion-deletion polymorphism in Alzheimer disease. Nature Genet1999; 22: 19–21.56. Rudrasingham V, Wavrant-De Vrièze F, Lambert J-C et al. a-2Macroglobulin gene and Alzheimer disease. Nature Genet 1999; 22:17–19.57. Hardy J. Amyloid, the presenilins and Alzheimer’s disease. TrendsNeurosci 1997; 20: 154–9.58. Kim W, Tanzi RE. Presenilins and Alzheimer’s disease. Curr OpinNeurobiol 1997; 7: 683–8.59. Kamboh M, Sanghera D, Ferrell R, DeKosky S. APOE 4-associatedAlzheimer’s disease risk is modified by 1-antichymotrypsin polymorphism.Nature Genet 1995; 10: 486–8.60. Thome J, Baumer A, Kornhuber J et al. Alpha-1-antichymotrypsinbi-allele polymorphism, apolipoprotein-E tri-allele polymorphismand genetic risk of Alzheimer’s syndrome. J Neur Transm 1995; 10:207–12.61. Muramatsu T, Matsushita S, Arai H et al. Alpha 1-antichymotrypsingene polymorphism and risk for Alzheimer’s disease. J Neur TransmParkinson’s Dis Dement 1996; 103: 1205–10.62. Talbot C, Houlden H, Craddock N et al. Polymorphism in AACTgene may lower age of onset of Alzheimer’s disease. NeuroReport1996; 7: 534–6.63. Yoshiiwa A, Kamino K, Yamamoto H et al. a 1 -antichymotrypsin as arisk modifier for late-onset Alzheimer’s disease in Japanese apolipoproteinE E4 allele carriers. Ann Neurol 1997; 42: 115–17.64. Egensperger R, Herrmann H, Kosel S, Graeber MB. Associationbetween ACT polymorphism, and Alzheimer’s disease. Neurology1998; 50: 575.65. Ezquerra M, Blesa R, Tolosa E et al. a 1 Antichymotrypsin genepolymorphism and risk for Alzheimer’s disease in the Spanishpopulation. Neurosci Lett 1998; 240: 107–9.66. Lamb H, Christie J, Singleton AB et al. Apolipoprotein E and a-1antichymotrypsin polymorphism genotyping in Alzheimer’s diseaseand in dementia with Lewy bodies: distinctions between diseases.Neurology 1998; 50: 388–91.67. Nacmias B, Marcon G, Tedde A et al. Implication of a1-antichymotrypsinpolymorphism in familial Alzheimer’s disease. NeurosciLett 1998; 244: 85–8.